 Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Satish Garg and Halis Akturk.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
7.024 |
|
|
|
-
Akturk HK, Garg S. Technological advances shaping diabetes care. Curr Opin Endocrinol Diabetes Obes. 2019 04; 26(2):84-89.
Score: 0.704
-
Akturk HK, Snell-Bergeon JK, Rewers A, Klaff LJ, Bode BW, Peters AL, Bailey TS, Garg SK. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. Diabetes Technol Ther. 2018 10; 20(10):639-647.
Score: 0.678
-
Akturk HK, Rewers A, Garg SK. SGLT inhibition: a possible adjunctive treatment for type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2018 08; 25(4):246-250.
Score: 0.672
-
Garg SK, Akturk HK. A New Era in Continuous Glucose Monitoring: Food and Drug Administration Creates a New Category of Factory-Calibrated Nonadjunctive, Interoperable Class II Medical Devices. Diabetes Technol Ther. 2018 06; 20(6):391-394.
Score: 0.666
-
Garg SK, Rewers AH, Akturk HK. Ever-Increasing Insulin-Requiring Patients Globally. Diabetes Technol Ther. 2018 06; 20(S2):S21-S24.
Score: 0.665
-
Akturk HK, Rewers A, Joseph H, Schneider N, Garg SK. Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes. Diabetes Technol Ther. 2018 06; 20(S2):S224-S232.
Score: 0.664
-
Garg SK, Rewers AH, Akturk HK. New Medications for the Treatment of Diabetes. Diabetes Technol Ther. 2018 02; 20(S1):S139-S153.
Score: 0.650
-
Garg SK, Akturk HK. The Future of Continuous Glucose Monitoring. Diabetes Technol Ther. 2017 06; 19(S3):S1-S2.
Score: 0.620
-
Garg SK, Akturk HK. Flash Glucose Monitoring: The Future Is Here. Diabetes Technol Ther. 2017 May; 19(S2):S1-S3.
Score: 0.616
-
Garg SK, Kipnes M, Castorino K, Bailey TS, Akturk HK, Welsh JB, Christiansen MP, Balo AK, Brown SA, Reid JL, Beck SE. Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. Diabetes Technol Ther. 2022 06; 24(6):373-380.
Score: 0.215
-
Garg SK, Liljenquist D, Bode B, Christiansen MP, Bailey TS, Brazg RL, Denham DS, Chang AR, Akturk HK, Dehennis A, Tweden KS, Kaufman FR. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technol Ther. 2022 02; 24(2):84-92.
Score: 0.208
-
Akturk HK, Snell-Bergeon J, Pyle L, Fivekiller E, Garg S, Cobry E. Accuracy of a breath ketone analyzer to detect ketosis in adults and children with type 1 diabetes. J Diabetes Complications. 2021 11; 35(11):108030.
Score: 0.208
-
Akturk HK, Giordano D, Champakanath A, Brackett S, Garg S, Snell-Bergeon J. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. Diabetes Obes Metab. 2020 04; 22(4):583-589.
Score: 0.185
-
Garg SK, Shah VN, Akturk HK, Beatson C, Snell-Bergeon JK. Role of Mobile Technology to Improve Diabetes Care in Adults with Type 1 Diabetes: The Remote-T1D Study iBGStar? in Type 1 Diabetes Management. Diabetes Ther. 2017 Aug; 8(4):811-819.
Score: 0.155
-
Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, Klaff LJ, Rosenstock J, Cheng MHM, Bode BW, Bautista ED, Xu R, Yan H, Thai D, Garg SK, Klein S. Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2023 Nov; 29(11):2959.
Score: 0.060
-
Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, Klaff LJ, Rosenstock J, Cheng MHM, Bode BW, Bautista ED, Xu R, Yan H, Thai D, Garg SK, Klein S. Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial. Nat Med. 2022 10; 28(10):2092-2099.
Score: 0.056
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|